緩和ケアと医学

抽象的な

Analysis of Nausea and Vomiting Induced by Three-Day as Compared with Single-Day Cisplatin-Based Chemotherapy

Ping Xiao, Ming Ding, Jingyue Zhang, Yinjuan Sun, Fanlu Meng, Xia Liu, Liyan Gu, Shasha Guan, Ai Gao, Zhicui Ju, Diansheng Zhong

Background: Three-day cisplatin-based chemotherapy, which is related to reduce side effects, has been widely used in clinical practice in China. However, whether three-day cisplatin could reduce chemotherapy-induced nausea and vomiting (CINV) as compared with single-day cisplatin-based regimens was still obscure.

Methods: Patients received single-day cisplatin-based (75 mg/m2) chemotherapy or three-day cisplatin-based (25 mg/m2/day) chemotherapy and treated with neurokinin-1 receptor antagonist (NK-1 RA)-based triple regimens were selected. With the methods of liquid chromatography mass spectrometry (LC-MS/MS), the blood concentration of cisplatin was analyzed. Simultaneously, the complete response (CR) rate and complete protection (CP) rate were evaluated within 5 days after initiation cisplatin-based chemotherapy.

Results: Two hundred and sixty patients (sixty patients received single-day cisplatin-based chemotherapy and two hundred patients received three-day cisplatin-based chemotherapy) were selected. From the 4th day, the blood concentration of cisplatin in three-day cisplatin was higher than that in single-day cisplatin-based treatment and the difference was statistically significant (P < 0.05). In addition, the CR rate in the acute, delayed and overall phases were achieved in 96.7% vs 92.50%, 85% vs 88.50% and 83.3% vs 87.5% between the two groups. The CP rate were obtained in 78.33% vs 74%, 48% vs 44.5%, 46.67% vs 43.5%, respectively. Both showed no significant difference (P > 0.05).

Conclusion: Even though the blood concentration between single-day and three-day cisplatin regimens was different, the incidence of CINV was not significantly different between the two groups with the usage of NK-1 RAbased antiemetic agents.